ID   CL1-R2
AC   CVCL_XK34
DR   Wikidata; Q93454206
RX   Patent=US10208124;
RX   PubMed=12486241;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3204.
CC   Monoclonal antibody isotype: IgG1.
CC   Monoclonal antibody target: UniProtKB; O95971; Human CD160.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
CA   Hybridoma
DT   Created: 19-12-19; Last updated: 21-03-23; Version: 4
//
RX   Patent=US10208124;
RA   Le Bouteiller P., Bensussan A.;
RT   "Anti-CD160 specific antibodies for the treatment of eye disorders
RT   based on neoangiogenesis.";
RL   Patent number US10208124, 19-Feb-2019.
//
RX   PubMed=12486241; DOI=10.1073/pnas.012681099;
RA   Le Bouteiller P., Barakonyi A., Giustiniani J., Lenfant F.,
RA   Marie-Cardine A., Aguerre-Girr M., Rabot M., Hilgert I.,
RA   Mami-Chouaib F., Tabiasco J., Boumsell L., Bensussan A.;
RT   "Engagement of CD160 receptor by HLA-C is a triggering mechanism used
RT   by circulating natural killer (NK) cells to mediate cytotoxicity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16963-16968(2002).
//